Newtyn Management’s Atea Pharmaceuticals AVIR Stock Holding History

Newtyn Management’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-492,284	Closed	-$1.43M	–	34
2025 Q3	$1.43M	Sell	492,284 -87,716	-15%	-$300K	0.17%	31
2025 Q2	$2.09M	Hold	580,000	–	–	0.32%	32
2025 Q1	$1.73M	Hold	580,000	–	–	0.27%	28
2024 Q4	$1.94M	Buy	580,000 +200,000	+53%	+$665K	0.34%	29
2024 Q3	$1.27M	Hold	380,000	–	–	0.2%	37
2024 Q2	$1.26M	Sell	380,000 -20,000	-5%	-$74.6K	0.24%	34
2024 Q1	$1.62M	Sell	400,000 -108,474	-21%	-$425K	0.32%	33
2023 Q4	$1.55M	Buy	508,474 +108,474	+27%	+$329K	0.3%	35
2023 Q3	$1.2M	Buy	400,000 +310,803	+348%	+$1.06M	0.3%	37
2023 Q2	$334K	Buy	+89,197	New	+$334K	0.08%	40

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Newtyn Management's AVIR Position: Q4 2025 in Review

Newtyn Management sold out of Atea Pharmaceuticals (AVIR) in Q4 2025, closing a stake of 492,284 shares — an estimated $1.43M sold.

Newtyn Management first reported a position in AVIR in Q2 2023 and held it in 10 quarters. The position peaked at $2.09M in Q2 2025. 111 funds tracked by Wall St. Rank hold AVIR as of Q4 2025.

Newtyn Management reported no remaining Atea Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Newtyn Management sold 492,284 Atea Pharmaceuticals shares in Q4 2025, an estimated $1.43M.
Newtyn Management first reported a position in Atea Pharmaceuticals in Q2 2023 and held it in 10 quarters.
Newtyn Management's Atea Pharmaceuticals position peaked at $2.09M in Q2 2025.
111 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2025.

Based on Newtyn Management's 13F filing for Q4 2025, filed 17 Feb 2026.